Early-onset rice body synovitis of the knee in children under three years: a case series and review of the literature - Scorecard - MDSpire

Early-onset rice body synovitis of the knee in children under three years: a case series and review of the literature

  • By

  • LunQing Zhu

  • Cong Liu

  • Yao Liu

  • BingQing Mao

  • YouHui Huang

  • Jun Wen

  • YiCong Liu

  • Tao Qian

  • June 12, 2026

  • 0 min

Share

Clinical Scorecard: Case Series and Literature Review of Early-Onset Rice Body Synovitis in Pediatric Patients Aged Three and Under

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingHospital-based treatment with outpatient follow-up

Key Highlights

  • outcomes

Guideline-Based Recommendations

Diagnosis

  • Clinical diagnostic features include knee swelling and limping
  • Imaging via X-ray and MRI to assess joint effusion and rice body-like lesions, with specific findings noted.

Management

  • Arthroscopic debridement for symptomatic knees
  • Postoperative treatment with ibuprofen and methotrexate, with a detailed tapering schedule.

Monitoring & Follow-up

    Risks

      Patient & Prescribing Data

      Combination of ibuprofen and methotrexate, with gradual tapering based on symptom improvement, specifying timelines.

      Clinical Best Practices

      • monitoring

      Related Resources & Content

      Original Source(s)

      Early-onset rice body synovitis of the knee in children under three years: a case series and review of the literature

      • by LunQing Zhu, Cong Liu, Yao Liu, BingQing Mao, YouHui Huang, Jun Wen, YiCong Liu, Tao Qian

      • June 12, 2026

      Related Content

      May Ultraprocessed Foods Raise Muscle Fat?

      MRI study suggests higher intake is associated with greater intramuscular fat in patients at risk for knee osteoarthritis.

      The Loan Cap That Could Shrink the Doctor Pipeline

      New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

      Dupilumab Gains Pediatric CSU Approval

      Targets type 2 inflammation in a population with limited treatment options